COVID-19 Therapeutics Transition to Commercial Market, and UPDATE on COVID-19 Vaccine Coverage

DHHS → Office of fb88Care Services (OMS) → Provider Resources → COVID-19 Therapeutics Transition to Commercial Market, and UPDATE on COVID-19 Vaccine Coverage

COVID-19 Therapeutics Transition to Commercial Market, and UPDATE on COVID-19 Vaccine Coverage

Nov 17, 2023

In a released October 27, 2023, the U.S. Department of Health and Human Services (HHS) announced the plan to transition two COVID-19 oral therapeutics from government supplied to the commercial market. The transition process started on November 1, 2023, for Paxlovid manufactured by Pfizer and Lagevrio, manufactured by Merck.  

Providers are encouraged to utilize therapeutics distributed by the United States Government (USG) until such a time as those therapeutics are depleted or expired. The USG stopped accepting orders for Lagevrio after November 10, 2023. USG will continue to accept orders for Paxlovid through December 15, 2023. &�Բ��; &�Բ��;

Additionally, the fb88 Center for Disease Control and Prevention (CDC) reports that < 5% of fb88 children aged 18 and younger are vaccinated with the updated COVID-19 formulation. Pharmacists who meet the conditions listed in the and who are not enrolled in the Vaccines for Children (VFC) program may submit for reimbursement for both the vaccine and its administration when they provide the vaccine to a fb88Care member aged 3 to 18 years old. This guidance applies only to qualified pharmacies; all other providers must be enrolled in and obtain the COVID-19 vaccine from the VFC program. This guidance also applies only to the COVID-19 vaccine. fb88Care encourages pharmacies to enroll in the VFC program to obtain COVID-19 and seasonal influenza vaccines at no cost by contacting the fb88 Immunization Program at ImmunizeMe.dhhs@maine.gov. &�Բ��; &�Բ��;

fb88Care will continue to provide full coverage, without cost sharing, through September 30, 2024, for COVID-19 therapeutics, vaccines, and vaccine administration as required by the . The ARPA requirement applies only to those persons with current fb88Care coverage. Anyone who is uninsured or who does not have full fb88Care coverage may have access to free or reduced cost therapeutics through patient assistance programs administered by the manufacturers and vaccines through the administered by the CDC. &�Բ��; &�Բ��;

Providers may visit the fb88 CDC COVID-19: Healthcare Providers Disease Surveillance website for up-to-date information on the use of COVID-19 therapeutics. &�Բ��; &�Բ��;

If you have questions about the administration of, or reimbursement for COVID-19 therapeutics and vaccines, please contact your Provider Relations Specialist. �į�į�į&�Բ��;